UCSF

UC San Francisco Previously Published Works

Title

Changes in specific domains of sexual function and sexual bother after radical prostatectomy.

Permalink

<https://escholarship.org/uc/item/0hm0r6jf>

Journal

BJU international, 106(7)

ISSN

1464-4096

Authors

Le, Jesse D
Cooperberg, Matthew R
Sadetsky, Natalia
et al.

Publication Date

2010-10-01

DOI

10.1111/j.1464-410x.2010.09231.x

Peer reviewed

Changes in specific domains of sexual function and sexual bother after radical prostatectomy

Jesse D. Le, Matthew R. Cooperberg, Natalia Sadetsky, Adam B. Hittelman*, Maxwell V. Meng, Janet E. Cowan, David M. Latini[†], Peter R. Carroll and the CaPSURE Investigators

*University of California San Francisco, San Francisco, CA, *Yale School of Medicine, New Haven, CT, and [†]Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX, USA*

Accepted for publication 9 November 2009

Study Type – Therapy (outcomes research)
Level of Evidence 2c

OBJECTIVE

To quantitatively assess the effect of radical prostatectomy (RP) on the specific domains that comprise overall sexual function (SF), focusing on the relationships among these domains and overall SF, and to identify predictors for recovery of SF over time, as a decline in SF and sexual bother (SB) are known potential complications of treatment for prostate cancer.

PATIENTS AND METHODS

Within the Cancer of the Prostate Strategic Urologic Research Endeavor database, we identified men diagnosed between 1995 and 2001 with localized prostate cancer treated with RP. SF and SB outcomes, measured using the University of California Los

Angeles Prostate Cancer Index, were assessed at 6-month intervals for 4 years after RP.

RESULTS

In all, 620 men met the study criteria; at 6 months after RP, overall and all the specific domains of SF declined, with improvement in most specific domains by 2 years after RP. The greatest declines were in the ability to achieve erections, high-quality erections, and frequent erections; these domains were also most strongly correlated with overall SF. Sexual desire was relatively preserved, and there was a weak correlation between overall SF and sexual desire after RP, when there was the greatest discrepancy between sexual desire and other domains of function. SB showed continued improvement over time to 4 years but was not well correlated with any measurements of SF assessed. Younger age, college education, sexual aid and medication use, the absence of comorbid conditions, and nerve-sparing surgery were

predictive of significant recovery of function in several specific domains of SF.

CONCLUSIONS

RP affects specific domains of SF to differing degrees. Compromised erectile function is most commonly reported among these specific domains and seems to play a more dominant role in determining overall SF, but notably none of the domains of function were closely linked to SB. Because education is protective in the perception of bother, appropriate counselling and the setting of expectations for outcomes in overall and specific domains of SF might lead to improved quality of life after treatment for prostate cancer.

KEYWORDS

prostate cancer, radical prostatectomy, sexual function, sexual bother, quality of life

INTRODUCTION

Prostate cancer represents the second leading cause of cancer mortality and is the most common noncutaneous cancer in American men, with an estimated 192 280 new diagnoses in 2009 [1]. Whereas historically physicians have focused on recurrence and survival as the primary outcomes of interest with interventions for prostate cancer, the success of various therapeutic options and stage migration to more pathologically organ-confined cancers [2,3], and the protracted natural history of the disease [4],

have led to a greater focus on other outcomes of treatment, specifically issues focused on health-related quality of life (HRQL).

Many studies have been conducted to compare HRQL outcomes [5–8]. HRQL issues clearly play a role in the decision-making process, and studies have suggested that patients might choose specific treatments to optimize HRQL over survival [9]. Among the various forms of treatment, general HRQL appears to be mostly unaffected and patient satisfaction equivalent [5]. However, disease-specific HRQL outcomes vary among

treatments in many domains. Decreased sexual function (SF) is a well-known potential complication of all active treatments for prostate cancer, including radical prostatectomy (RP) [10]. SF is multifaceted, and the effect of treatment on its specific domains has also been examined, including the effect of surgery on erections and successful intercourse [11,12], sexual desire [13], and orgasm and ejaculation [14,15]. In addition, studies evaluating the effect of RP on sexual bother (SB) have also been reported [10,16]. Although the effects of prostate cancer treatment on SF specific domains have

FIG. 1. (a) Overall SF scores after RP; a high baseline SF was defined as a PCI SF summary score of 80–100; (b) SB scores after RP.

previously been reported, less attention has been focused on the interaction among these domains.

The goal of this study was to assess the effect of RP on specific domains of SF, focusing on the relationships among these domains and overall SF and SB. This knowledge will assist physicians and patients in anticipating outcomes, educating and managing expectations, and facilitating preoperative decision-making.

PATIENTS AND METHODS

Participants were men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study, a longitudinal, observational disease registry for men with biopsy confirmed prostate cancer. The CaPSURE database contains demographic, clinical, treatment and outcomes data for >13 000 men with prostate cancer treated at 40 clinical sites nationwide. Men are recruited by urologists at each site, and they complete a self-administered questionnaire upon enrolment into the study and every 6 months

thereafter. CaPSURE questionnaires include the University of California Los Angeles (UCLA) Prostate Cancer Index (PCI) survey to assess HRQL [17].

Clinical variables collected include PSA level at diagnosis, Gleason score, clinical T stage, body mass index, presence of specific pretreatment comorbidities related to SF (such as hypertension, heart disease, stroke, diabetes, kidney disease, and urinary conditions including dysuria, haematuria and LUTS), and use of phosphodiesterase-5 inhibitors or sexual aids. Clinical risk categories were based on a modification of the risk groups of D'Amico *et al.* [18]. Patients were considered as: low-risk if they had a PSA level of <10 ng/mL, Gleason sum of <7 with no primary or secondary Gleason of 4 or 5, and clinical stage T1–T2a; intermediate-risk if they had a PSA level of 10.1–20 ng/mL, Gleason sum 7 or Gleason secondary 4 or 5, or T stage cT2b–2c; and high-risk if they had a PSA level of >20 ng/mL, Gleason sum >7 or Gleason primary 4 or 5, or T stage cT3a. More detailed descriptions of the CaPSURE project methods are described elsewhere [19].

Patients with ≥4 years of follow-up data who were newly diagnosed at enrollment and who had RP as the primary treatment from 1995 to 2001 were included in this study. Patients who received neoadjuvant and/or adjuvant therapy were excluded; 620 patients thus constituted the analytic dataset.

The UCLA PCI is a self-reported questionnaire that measures sexual, urinary, and bowel function and bother for men with prostate cancer. The measure has been used extensively in research on prostate cancer HRQL, and has been shown to be both reliable and valid when used as a summary measure [17]. In terms of SF, this analysis focuses on eight subscale questions (sexual desire, ability to achieve erections, ability to achieve orgasm, quality of erections, frequency of erections, awakening with an erection, frequency of intercourse, and SF in the last 4 weeks). Responses to these questions contribute to the SF summary score. The PCI assesses the amount of associated bother measured with one question on patients' SB in the last 4 weeks. In the present study we used responses to the PCI SF subscale questions as a measure of specific domains of SF, and we used the SF summary score as a measure of overall SF.

Specific domains are scored on 3-, 4- and 5-point scales, and are scaled relative to a maximum of 100 points. Higher scores indicate better HRQL. We created binary outcome variables for specific domains of SF based on thresholds for high and low functioning in each of these areas. Six outcomes were defined according to previous work by Krupski *et al.* [20], and the remaining four were adapted to the PCI from the Prostate Cancer Outcomes Study items and standards proposed by Penson *et al.* [11]. Throughout this report a high SF was defined as an overall SF score of ≥80, as defined by Krupski *et al.* [20].

The demographic and clinical characteristics at baseline were evaluated by chi-square analysis for categorical and ANOVA for continuous variables. Cronbach's α was calculated to assess internal consistency. The Pearson correlation coefficient (r) was used to test the strength of correlation among specific domains and overall SF. The association between binary outcome variables for specific domains and various clinical and demographic variables over time was evaluated with a generalized linear regression model. These repeated measures models used generalized estimating equations to account for multiple comparisons of discrete, correlated outcomes. Analyses modelled the probability of achieving high function in each SF domain.

RESULTS

The characteristics of the 620 patients analysed are summarized in Table 1; the mean (SD) age was 61.4 (6.8) years. Most patients had low- to intermediate-risk characteristics, including a PSA level of ≤10 ng/mL (86%), stage T1 or T2 (98%) and a Gleason score of ≤6 (76%). Reliability analysis of the sample showed that responses to the PCI questionnaire had high internal consistency at baseline (Cronbach's α , 0.92), 1 year (0.90) and 2 years after RP (0.90).

We compared trends in overall SF over time in all patients with trends for subpopulations stratified by low (0–79) and high (80–100) baseline overall SF [20] (Fig. 1a). Only 28% of men met the criteria for a high baseline overall SF. This subset of patients had a nadir in function at 6 months after RP, with partial recovery of function to a mean (SD) overall SF score of 53 (25) at 2 years after RP. Patients

TABLE 1 The demographic and clinical characteristics of patients undergoing RP

Variable	n (%)
Demographic	
Age at diagnosis, years	
<60	241 (39)
60–64	155 (25)
≥65	224 (36)
Race	
White	554 (89)
Other	66 (11)
Education	
High school graduate or less	205 (33)
Some college	119 (19)
College graduate	292 (47)
Income level	
Low	289 (49)
Intermediate	216 (37)
High	81 (14)
Relationship	
In a relationship	580 (94)
Single	35 (6)
Insurance	
Medicare and supplement	124 (20)
Medicare	57 (9)
Private	393 (63)
Other/None	46 (7)
Clinical	
PSA level, ng/mL	
≤4	88 (15)
4.1–10	423 (71)
10.1–20	69 (12)
>20	18 (3)
Clinical T stage	
T1	324 (54)
T2	261 (44)
T3	12 (2)
Biopsy Gleason total	
2–4	15 (2)
5–6	447 (74)
7	127 (21)
8–10	19 (3)
Clinical risk category	
Low	289 (49)
Intermediate	216 (37)
High	81 (14)
Nerve-sparing RP	
No	127 (20)
Yes	413 (67)
Unknown	80 (13)
Body mass index (kg/m ²)	
Normal (<25.0)	155 (25)
Overweight (25.0–29.9)	348 (57)
Obese (≥30.0)	110 (18)
SF-related comorbidities	
None	282 (46)
1	227 (37)
≥2	107 (17)
ED medication at 6 months after RP	127 (20)
Use of sexual device	121 (20)

Categories might not total to N due to missing values. Percentages might not total 100 due to rounding.

FIG. 2. The percentage of men reporting high function in specific domains of SF after RP. High function in specific domains is defined in Table 2.

FIG. 3. The percentage of men with a high baseline SF reporting high function in specific domains of SF after RP. High baseline SF was defined as a PCI SF summary score of 80–100. High function in specific domains is defined in Table 2.

with a low overall SF score at baseline also recovered function over the same period, with a mean score of 25 (22) at 2 years. There was no additional improvement in mean overall SF score in either group at 4 years after RP. However, patients in both groups continued to have less bother over time (Fig. 1b). At 4 years, the SB score for the high-baseline SF group was 58 (36) and for the low-baseline SF group was 45 (39).

To assess changes in specific domains of SF, we assessed the percentage of men reporting high function in each domain after RP (Fig. 2); high function thresholds are defined in

Table 2. Most men reported at least some compromise at baseline, with the most baseline dysfunction reported in frequency of erection and awakening with erections. The largest declines in function from before treatment to 4 years after RP were in the ability to achieve erections, quality of erections, and awakening with erections. The least change was in sexual desire, but it was less likely to improve over time. Performance in all other specific domains improved between 6 months and 2 years after RP. The pattern of effect on specific domains of SF was similar when considering men with a high baseline SF (Fig. 3). Patients reported

TABLE 2 Specific domain definitions for high and low SF

PCI component (in last 4 weeks)	High function	Low function	Source
Level of sexual desire	Very good Good	Fair Poor Very Poor	[11]
Ability to have an erection	Very good Good	Fair Poor Very Poor	[11]
Ability to reach orgasm	Very good Good	Fair Poor Very poor	[11]
Usual quality of erections	Firm enough for intercourse	Firm enough for masturbation and foreplay only Not firm enough for any sexual activity	[20]
Frequency of erections	Whenever I wanted	None at all More than half the time About half the time Less than the time Never	[20]
Awakening with an erection	Very often Often	Not often Seldom Never	[20]
Frequency of intercourse	Yes, more than once Yes, once	None	[20]
SF	Very good Good	Fair Poor Very poor	[20]
SB	No problem Very small problem	Small problem Moderate problem Big problem	[11]
Overall SF score	80–100	<80	[20]

reduced SB over the entire study period, with 40% of all men and 47% of men with high SF scores at baseline reporting 'no problem' or a 'very small problem' with their given level of function at 4 years after RP.

The strength of correlations among overall SF and its specific domains varied greatly. Table 3 shows Pearson's correlation coefficients at 6 months after RP; overall SF was most strongly correlated with the ability to achieve erections, erection quality, and erection frequency, and SF in the last 4 weeks. There were also relatively strong correlations between overall SF and the ability to achieve orgasm and frequency of intercourse. However, overall SF was only weakly correlated with sexual desire and awakening with erections. In terms of sexual desire, the correlation between overall SF and sexual desire decreased markedly from a baseline $r = 0.75$ (not shown in Table 3) to 0.52 at 6 months after RP. When considering the correlation between the subscale question specifically assessing SF over the last 4 weeks with the other subscale questions, the trends were similar. None of the specific domains of SF had a strong correlation with SB.

Repeated-measures regression models were used to identify predictors of improvement for each specific domain of SF, controlling for multiple variables over time. Significant improvements in function were associated with younger age, erectile device and medication use, RP nerve-sparing surgery, more education, and the absence of comorbid conditions. The odds of having high function in each specific domain for various

TABLE 3 Pearson's correlation coefficient among overall SF, SB and specific domain scores at 6 months after RP

Domain	Sexual desire	Achieve erection	Achieve orgasm	Erection quality	Erection frequency	Awaken with erection	Intercourse frequency	SF last 4 weeks
Sexual desire	1.00							
Achieve erection	0.23	1.00						
Achieve orgasm	0.47	0.47	1.00					
Erection quality	0.26	0.71	0.49	1.00				
Erection frequency	0.19	0.73	0.40	0.67	1.00			
Awaken with erection	0.09	0.54	0.18	0.48	0.51	1.00		
Intercourse frequency	0.23	0.45	0.40	0.50	0.40	0.25	1.00	
SF last 4 week	0.29	0.76	0.55	0.67	0.70	0.45	0.64	1.00
SB last 4 week	*	0.38	0.21	0.27	0.41	0.22	0.14	0.44
Overall SF	0.52	0.81	0.72	0.83	0.77	0.53	0.71	0.86

All $P < 0.01$, except * not significant. Comparisons omitted where redundant.

TABLE 4 Results of generalized estimating equations repeated-measures analysis of binary outcomes adjusted for demographic and clinical characteristics

Comparison	Sexual desire	Achieve erection	Achieve orgasm	Erection quality	Erection frequency	Awaken with erection	Intercourse last 4 weeks	SF last 4 weeks	SB last 4 weeks
Age									
60–64 vs ≥65	1.65 (1.16–2.36)*	1.64 (1.07–2.51)	1.68 (1.16–2.44)*	1.57 (1.05–2.33)	–	–	1.61 (1.11–2.35)	1.56 (1.04–2.36)	–
<60 vs ≥65	1.55 (1.12–2.14)*	2.11 (1.43–3.12)*	2.22 (1.60–3.13)*	2.16 (1.50–3.12)*	1.92 (1.31–2.83)*	1.83 (1.18–2.86)*	1.86 (1.31–2.63)*	1.95 (1.34–2.84)*	–
ED device use									
No vs yes	–	–	0.70 (0.50–0.99)	–	–	–	0.33 (0.23–0.47)*	–	2.00 (1.43–2.80)*
ED medication use									
No vs yes	–	–	0.72 (0.54–0.97)	0.68 (0.49–0.94)	–	–	0.61 (0.46–0.82)*	–	2.04 (1.47–2.83)*
Education									
≤High school vs college degree	–	0.47 (0.32–0.68)*	0.66 (0.48–0.91)	–	0.60 (0.41–0.87)*	–	–	0.56 (0.39–0.81)*	0.50 (0.37–0.68)*
Some college vs college degree	–	0.60 (0.39–0.93)*	–	–	–	–	–	–	0.62 (0.44–0.88)*
Nerve-sparing RP									
No vs yes	0.54 (0.37–0.79)*	0.49 (0.31–0.78)*	0.51 (0.34–0.76)*	0.39 (0.25–0.60)*	0.50 (0.31–0.80)*	0.57 (0.33–0.97)	0.45 (0.30–0.68)*	0.47 (0.30–0.73)*	–
Unknown vs yes	–	–	–	–	–	–	0.53 (0.31–0.89)*	–	–
SF-related comorbidities									
1 vs none	–	0.59 (0.41–0.83)*	0.64 (0.47–0.87)*	–	0.61 (0.43–0.87)*	–	–	0.65 (0.46–0.91)	0.73 (0.55–0.97)
≥2 vs none	–	0.42 (0.26–0.69)*	0.64 (0.43–0.96)	–	0.43 (0.26–0.70)*	0.46 (0.25–0.84)	0.57 (0.37–0.87)*	0.57 (0.36–0.90)	0.68 (0.47–0.99)

Odds ratio of achieving high function in each specific domain given with 95% CI when significant ($P < 0.05$, except where * $P < 0.01$).

comparison groups are given in Table 4. There were no significant trends with race, relationship status, or clinical risk group.

DISCUSSION

The management of localized prostate cancer remains controversial, and most patients with early-stage disease have several treatment options available. Downward stage migration at diagnosis and improved cancer-specific survival have lead to a greater focus on treatment-related morbidity and HRQL. Although much information has been collected on SF after RP, less focus has been placed on the specific domains of function that comprise SF and the interaction between these specific domains and the assessment of overall SF. In the present analysis we evaluated SF outcomes, focusing on the effect

of RP on specific domains of SF as measured by the PCI survey [17] in the CaPSURE population. We hypothesized that while an overall assessment of SF offers a general summary, surgery affects specific domains of function differently, and that further, these specific domains of SF vary in their relative contributions to overall SF. This type of analysis might provide new information for patients and physicians about how SF changes after RP, and offers an opportunity for education and intervention.

Our study outlines the baseline and longitudinal outcomes of both overall and specific domains of SF in a group of men undergoing RP. Many patients have compromised SF at baseline. The largest declines were in the four erection domains (ability to achieve erections, erection frequency, erection quality, awakening with

erections), and the least decline was in sexual desire. There were declines in all specific domains at 6 months, with improvement of most domains at 2 years. This finding was similar to that in a study by Penson *et al.* [11], that evaluated sexual outcomes after RP, confirming a nadir of SF at 6 months, and noting improvement at 2 years, with a small minority steadily improving through to 5 years. The findings were similar when we examined the subset of patients with higher baseline SF. There was a large variation in our study population, but the degree of SB that men experienced seemed to improve over the 4-year study interval, despite a less robust improvement in function from 2 to 4 years after RP.

Analysis of the correlation between overall SF and specific domains showed the strongest correlations with three of four erection

domains assessed by the PCI (ability to achieve, frequency, and quality). Overall SF scores reflect an averaged scaled score of each specific domain [17], and because four of the eight PCI domains assess erections, a strong correlation between erections and overall SF might be expected. To overcome this possible bias, we examined correlations between patient-reported SF in the past 4 weeks and other domains of function; we also saw a similar pattern here.

Weaker correlations with frequency of intercourse and awakening with erections indicate that these domains might not play as dominant role in driving perceived overall SF, or possibly that men tend to define their SF largely in terms of their erections. The correlation between SF and sexual desire decreased markedly after RP. This result shows a more complex interaction between sexual desire and SF, given that the relative preservation of sexual desire after surgery concurrent with larger functional losses in other domains is not strongly linked to the perception of preserved SF. As previously reported by Dahn *et al.* [13], there might be a need to independently examine sexual desire in HRQL considerations when sexual desire and other domains of function diverge.

A recent review by Mulhall [21] found large variation in the acquisition and reporting of SF outcomes after RP. Among the variety of questionnaires available to investigators, the most commonly used validated questionnaires are the PCI (or its Expanded Prostate Index Composite, EPIC) [22] and the International Index of Erectile Function (IIEF) [23] (or its abbreviated IIEF-5 also known as the Sexual Health Inventory for Men, SHIM) [24]. In a review of the studies on SF in reports on cancer, the National Institutes of Health's Cancer Patient-Reported Outcomes Measurement Information System group reported that the PCI/EPIC was used in 34% and the IIEF/SHIM in 31% of 257 studies examined [25].

While the IIEF was developed to evaluate erectile dysfunction (ED) in general, the PCI was developed for disease-specific HRQL assessment in men with prostate cancer. Like the PCI, the IIEF also contains questions pertaining to the specific domains of erection, intercourse, orgasm, desire, and overall satisfaction with function. The SHIM includes only questions on erection as it pertains to intercourse. While the IIEF and SHIM have

validated diagnostic thresholds for the severity of ED [26,27], neither the PCI nor EPIC have such validated threshold ranges.

Given the widespread use of both of these questionnaire types, it is therefore important to consider the relationship between them, particularly how the PCI-derived results from this study can be interpreted in terms of the IIEF. Schroeck *et al.* [28] found a high degree of correlation between the SHIM and EPIC SF summary scores in men with prostate cancer, while noting that the EPIC seemed to provide more discriminating information at the highest and lowest spectrums of SF according to the SHIM, as these men had wide-ranging EPIC scores. While no similar studies exist relating specific domains of SF between the questionnaire types, it is reasonable to believe that these too might share similar trends. While the IIEF assesses only SF, the PCI assesses both SF and SB; thus our analysis of SB is unique to the PCI.

Previous studies reported that the most consistent predictors of compromised SF were non-nerve-sparing surgery, greater age at surgery, more pretreatment comorbidities, and a lower level of education [10–12,29–31]. In the present study, we examined patient demographic and clinical characteristics as predictors of improvement in specific domains of SF and confirm these findings. Although education correlated with age and race in the present cohort, Knight *et al.* [31] identified it as an independent predictor of SF in a group of men in the Veterans Affairs Health Care System, in which access to care is even across sociodemographic groups.

Previous work showed that up to 75% of patients will not use sexual aids after RP [32], and that many patients will discontinue using sexual aids within a year after surgery, despite effectively attaining erections while using them [33]. In the present study, 20% of patients reported using some ED device after RP, and 20% reported using medications at 6 months of follow-up. There was a significant association between the use of phosphodiesterase-5 inhibitors and devices for ED, and improvements in erection quality, orgasm, and frequency of intercourse. Patients not using sexual aids were twice as likely to report improved SB, but unfortunately the question of whether SB was a cause or result of men using ED devices and medications cannot be fully addressed by this study.

Previous studies showed that SF and SB do not always correlate, as perception of the problem does not necessarily reflect the level of dysfunction [10,16]. The present study showed that SB was not closely correlated to any of the other measures of SF as measured by the PCI, a widely used survey to assess HRQL. This finding reiterates the complexity of the relationship between SF and perceived SB that patients experience. We found that those men with a high school education or less were half as likely to have reduced SB than were college graduates. Knight *et al.* [31] also found a correlation between low education level and poor SF outcomes after RP, indicating that patients' understanding and interpretation of surgical outcomes might make them vulnerable to adverse HRQL outcomes. Thus, if education is protective against poor SF outcomes, an increased effort to provide preoperative counselling, and provide more realistic expectations of treatment outcomes and assistance in managing treatment-related adverse effects, might improve sexual outcomes.

This study has several limitations. The UCLA PCI is an instrument measuring overall function, representing the composite of specific domains of SF. Although this instrument provides a useful, broad definition of overall SF, we chose to examine the individual questions of the PCI to better understand how specific domains are affected by RP, with the intention of expanding the opportunities for intervention and/or education. The UCLA PCI questionnaire has been validated only as a unitary scale [17]; the individual items have not specifically been validated. While this might limit our ability to make definitive statements about each aspect of SF, we feel that the specific domain scores provide valuable information. Krupski *et al.* [20] also used individual specific domain scores to assess definitions of potency. In addition, we created binary thresholds for the components of SF to distinguish between high and low SF for each SF item. While some information is lost by collapsing our data in this manner, we feel that these stratifications provide a more clinically relevant means of assessing performance. Our definition for nerve-sparing surgery did not differentiate between unilateral and bilateral nerve-sparing, potentially diluting the improved outcomes of patients receiving bilateral nerve-sparing RP. Nevertheless, there were still significant differences in most outcomes evaluated. This study was a retrospective

analysis, and CaPSURE collects data without regard to hypothesis at sites not chosen at random. However, CaPSURE reflects a diverse mix of locations and practice types, and is one of the few large population-based cohorts available for longitudinal analysis. As such, we were able to study a patient population with comprehensive 4-year follow-up for HRQL data.

In conclusion, treatment for prostate cancer carries the potential risk of compromised SF and increased SB. RP affects specific domains of SF (e.g. assessment of erections, desire, orgasm, and intercourse) to differing degrees. While sexual desire is relatively preserved, compromise is most commonly reported in the assessment of erectile function, which seems to play a dominant role in shaping overall SF. None of the domains of function are closely linked to SB, but a higher level of education is predictive of a reduction in perceived SB. This underscores the importance of appropriate counselling in setting patients' expectations for the outcomes in specific domains of SF, which might lead to improved HRQL outcomes.

ACKNOWLEDGEMENTS

The current CaPSURE Investigators are:

Peter R. Carroll, MD (University of California, San Francisco, San Francisco, CA); James S. Cochran, MD (Urology Clinics of North Texas, Dallas, TX); Christopher J. Kane, MD (Veterans Administration Medical Center, San Francisco, CA); Donald P. Finnerty, MD (PAPP Clinic, Newnan, GA); Eugene V. Kramolowsky, MD (The Virginia Urology Center, Richmond, VA); Robert M. Segaul, MD (Urology Associates of West Broward, Sunrise, FL); Paul Sieber, MD (Urological Associates of Lancaster, Lancaster, PA); Stanley A. Brosman, MD (Pacific Urology Institute, Santa Monica, CA); Lynn W. Conrad, MD (The Conrad Pearson Clinic, Germantown, TN); Ronald A. Chee-Awai, MD (Urologic Institute of New Orleans, Marrero, LA); Michael Flanagan, MD (Urology Specialists, PC, Waterbury, CT); Jeffrey K. Cohen, MD (Triangle Urology Group, Pittsburgh, PA); Jerrold Sharkey, MD (Urology Health Center, New Port Richey, FL); Thomas W. Coleman, MD (Bay Urology Services, Mobile, AL); Elliott C. Silbar, MD (Clinic of Urology, SC, Milwaukee, WI); Paul S. Ray, DO (John H Stroger Hospital of Cook County, Chicago, IL); David Noyes, MD (Berkshire Urological Associates, PC, Pittsfield, MA); Mohammed Mostafavi, MD (Urology

Group of Western New England, Springfield, MA); Louis Keeler, III, MD (Delaware Valley Urology, LLC-Voorhees, Voorhees, NJ); James Gottesman, MD (Seattle Urological, Seattle, WA); Bhupendra M. Tolia, MD (Associated Advanced Adult & Paediatric Urology, Bronx, NY); Patrick P. Daily, MD (Mississippi Urology, Jackson, MS); Glen Wells, MD (Alabama Urology, Birmingham, AL); Richard J. Kahnoski, MD (Michigan Medical, PC Urology, Grand Rapids, MI); Sheldon J. Freedman, MD (Las Vegas, NV); Randil Clark, MD (North Idaho Urology, Coeur d'Alene, ID); Daniel W. Lin, M.D (Veterans Administration Puget Sound HCS, Seattle, WA); Mark Austenfeld, MD (Kansas City Urology Care, Kansas City, MO); Henri P. Lanctin, MD (Adult & Paediatric Urology, Sartell, MN); J. Brantley Thrasher, MD (University of Kansas, Adult Urology and Urologic Oncology, Kansas City, KS); David W. Bowyer, MD (Snake River Urology, Twin Falls, ID). **Former CaPSURE investigators are:** John Forrest, MD (1995–99, Urologic Specialists of Oklahoma, Tulsa, OK); William Schmeid, MD (1995–99, Metro Urology, Jeffersonville, IN); Glen Brunk, MD (1995–99, Urology of Indiana, Indianapolis, IN); Jay Young, MD (1995–2001, South Orange County Medical Research Center, Laguna Woods, CA); Gary Katz, MD (1996–2000, Medical College of Virginia and Veterans Administration Medical Center, Richmond, VA); Stacy J. Childs, MD (1999–2000, Cheyenne Urological, Cheyenne, WY); Kevin Tomera, MD (1999–2001, Alaska Urological Associates, Anchorage, AK); Clayton Hudnall, MD (1995–2002, Urology San Antonio Research, San Antonio, TX); David Penson, MD, MPH (2000–2003, Veterans Administration Puget Sound HCS, Seattle, WA); W. Lamar Weems, MD (1996–2005, Mississippi Urology, Jackson, MS); Joseph N. Macaluso, Jr., MD (1995–2005, Urologic Institute of New Orleans, Gretna, LA).

Support: CaPSURE was previously supported by TAP Pharmaceutical Products Inc. (Lake Forest, IL), and is currently funded internally by UCSF. This research was additionally funded by National Institutes of Health/ National Cancer Institute University of California-San Francisco SPORE Specialized Program of Research Excellence P50CA89520. Dr Latini is supported by Mentored Research Scholar Grant 06-083-01-CPPB from the American Cancer Society.

CONFLICT OF INTEREST

None declared.

REFERENCES

- 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009; **59**: 225–49
- 2 Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. *Eur Urol* 2000; **38**: 74–8
- 3 Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. *J Clin Oncol* 2005; **23**: 8146–51
- 4 Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA* 2005; **293**: 2095–101
- 5 Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. *J Urol* 2001; **166**: 947–52
- 6 Hu JC, Elkin EP, Pasta DJ *et al*. Predicting quality of life after radical prostatectomy: results from CaPSURE. *J Urol* 2004; **171**: 703–7
- 7 Litwin MS, Gore JL, Kwan L *et al*. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. *Cancer* 2007; **109**: 2239–47
- 8 White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. *J Urol* 2008; **180**: 2409–13
- 9 Albertsen PC, Nease RF, Potosky AL. Assessment of patient preferences among men with prostate cancer. *J Urol* 1998; **159**: 158–63
- 10 Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. *J Urol* 2003; **169**: 1653–61
- 11 Penson DF, McLerran D, Feng Z *et al*. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. *J Urol* 2008; **179**: S40–4
- 12 Schover LR, Fouladi RT, Warneke CL *et al*. Defining sexual outcomes after treatment for localized prostate carcinoma. *Cancer* 2002; **95**: 1773–85
- 13 Dahn JR, Penedo FJ, Gonzalez JS *et al*. Sexual functioning and quality of life after prostate cancer treatment:

- considering sexual desire. *Urology* 2004; **63**: 273–7
- 14 Koeman M, van Driel MF, Schultz WC, Mensink HJ. Orgasm after radical prostatectomy. *Br J Urol* 1996; **77**: 861–4
 - 15 Barnas JL, Pierpaoli S, Ladd P *et al*. The prevalence and nature of orgasmic dysfunction after radical prostatectomy. *BJU Int* 2004; **94**: 603–5
 - 16 Cooperberg MR, Koppie TM, Lubeck DP *et al*. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from. *Capsure Urol* 2003; **61**: 190–6
 - 17 Litwin MS, Hays RD, Fink A *et al*. Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care* 1998; **36**: 1002–12
 - 18 D'Amico AV, Whittington R, Malkowicz SB *et al*. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; **280**: 969–74
 - 19 Cooperberg MR, Broering JM, Litwin MS *et al*. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. *J Urol* 2004; **171**: 1393–401
 - 20 Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. *J Urol* 2003; **170**: 1291–4
 - 21 Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. *J Urol* 2009; **181**: 462–71
 - 22 Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology* 2000; **56**: 899–905
 - 23 Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997; **49**: 822–30
 - 24 Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *Int J Impot Res* 2005; **17**: 307–19
 - 25 Jeffery DD, Tzeng JP, Keefe FJ *et al*. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. *Cancer* 2009; **115**: 1142–53
 - 26 Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. *Urology* 1999; **54**: 346–51
 - 27 Rosen RC, Cappelleri JC, Smith MD, Lipsky J, PeÖa BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999; **11**: 319–26
 - 28 Schroeck FR, Donatucci CF, Smathers EC *et al*. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. *Cancer* 2008; **113**: 2687–94
 - 29 Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor). *Urology* 1999; **54**: 503–8
 - 30 Michl UH, Friedrich MG, Graefen M, Haese A, Heinzer H, Huland H. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. *J Urol* 2006; **176**: 227–31
 - 31 Knight SJ, Latini DM, Hart SL *et al*. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. *Cancer* 2007; **109**: 1769–76
 - 32 Stanford JL, Feng Z, Hamilton AS *et al*. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. *JAMA* 2000; **283**: 354–60
 - 33 Matthew AG, Goldman A, Trachtenberg J *et al*. Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. *J Urol* 2005; **174**: 2105–10

Correspondence: Peter R. Carroll, Department of Urology, University of California San Francisco/Mt. Zion Cancer Center, 1600 Divisadero St., 3rd Floor, San Francisco, CA 94115–1711, USA.
e-mail: pcarroll@urol.ucsf.edu

Abbreviations: CaPSURE, Cancer of the Prostate Strategic Urologic Research Endeavor; ED, erectile dysfunction; EPIC, Expanded Prostate Index Composite; HRQL, health-related quality of life; IIEF, International Index of Erectile Function; UCLA PCI, University of California Los Angeles Prostate Cancer Index; RP, radical prostatectomy; SB, sexual bother; SF, sexual function; SHIM, Sexual Health Inventory for Men.